File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo-controlled trial

TitleLamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo-controlled trial
Authors
Issue Date1997
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
Hepatology, 1997, v. 25 n. 1, p. 241-244 How to Cite?
AbstractLamivudine is a novel 2',3'-dideoxy cytosine analogue that has potent inhibitory effects on hepatitis B virus replication in vitro and in vivo. We performed a single-blind, placebo-controlled study to assess its effectiveness and safety in Chinese hepatitis B surface antigen (HBsAg) carriers. Forty-two Chinese HBsAg carriers were randomized to receive placebo (6 patients) or lamivudine orally in dosages of 25 mg, 100 mg, or 300 mg daily (12 patients for each dosage). The drug was given for 4 weeks. The patients were closely monitored clinically, biochemically, and serologically up to 4 weeks after drug treatment. All 36 patients receiving lamivudine had a decrease in hepatitis B virus (HBV) DNA values of >90% (P < .001 compared with placebo). Although 25 mg of lamivudine was slightly less effective than 100 mg (P = .011) and 300 mg (P = .005), it still induced 94% suppression of HBV DNA after the fourth week of therapy. HBV DNA values returned to pretreatment levels within 4 weeks of cessation of therapy. There was no change in the hepatitis B e antigen status or in aminotransferase levels. No serious adverse events were observed. In conclusion, a 4-week course of lamivudine was safe and effective in suppression of HBV DNA in Chinese HBsAg carriers. The suppression was >90% but reversible. Studies with long-term lamivudine administration should be performed to determine if prolonged suppression of HBV DNA can be achieved.
Persistent Identifierhttp://hdl.handle.net/10722/77771
ISSN
2015 Impact Factor: 11.711
2015 SCImago Journal Rankings: 4.752
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLai, CLen_HK
dc.contributor.authorChing, CKen_HK
dc.contributor.authorTung, AKMen_HK
dc.contributor.authorLi, Een_HK
dc.contributor.authorYoung, Jen_HK
dc.contributor.authorHill, Aen_HK
dc.contributor.authorWong, BCYen_HK
dc.contributor.authorDent, Jen_HK
dc.contributor.authorWu, PCen_HK
dc.date.accessioned2010-09-06T07:35:33Z-
dc.date.available2010-09-06T07:35:33Z-
dc.date.issued1997en_HK
dc.identifier.citationHepatology, 1997, v. 25 n. 1, p. 241-244en_HK
dc.identifier.issn0270-9139en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77771-
dc.description.abstractLamivudine is a novel 2',3'-dideoxy cytosine analogue that has potent inhibitory effects on hepatitis B virus replication in vitro and in vivo. We performed a single-blind, placebo-controlled study to assess its effectiveness and safety in Chinese hepatitis B surface antigen (HBsAg) carriers. Forty-two Chinese HBsAg carriers were randomized to receive placebo (6 patients) or lamivudine orally in dosages of 25 mg, 100 mg, or 300 mg daily (12 patients for each dosage). The drug was given for 4 weeks. The patients were closely monitored clinically, biochemically, and serologically up to 4 weeks after drug treatment. All 36 patients receiving lamivudine had a decrease in hepatitis B virus (HBV) DNA values of >90% (P < .001 compared with placebo). Although 25 mg of lamivudine was slightly less effective than 100 mg (P = .011) and 300 mg (P = .005), it still induced 94% suppression of HBV DNA after the fourth week of therapy. HBV DNA values returned to pretreatment levels within 4 weeks of cessation of therapy. There was no change in the hepatitis B e antigen status or in aminotransferase levels. No serious adverse events were observed. In conclusion, a 4-week course of lamivudine was safe and effective in suppression of HBV DNA in Chinese HBsAg carriers. The suppression was >90% but reversible. Studies with long-term lamivudine administration should be performed to determine if prolonged suppression of HBV DNA can be achieved.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/en_HK
dc.relation.ispartofHepatologyen_HK
dc.rightsHepatology. Copyright © John Wiley & Sons, Inc.en_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAdulten_HK
dc.subject.meshAntiviral Agents - therapeutic useen_HK
dc.subject.meshCarrier State - drug therapyen_HK
dc.subject.meshDNA, Viral - analysisen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHepatitis B - drug therapyen_HK
dc.subject.meshHepatitis B e Antigens - analysisen_HK
dc.subject.meshHepatitis B virus - drug effects - geneticsen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLamivudine - adverse effects - therapeutic useen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshSingle-Blind Methoden_HK
dc.titleLamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo-controlled trialen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0270-9139&volume=25&spage=241&epage=244&date=1997&atitle=Lamivudine+is+effective+in+suppressing+Hepatitis+B+virus+DNA+in+Chinese+hepatitis+B+surface+antigen+carriers:+a+placebo-controlled+trialen_HK
dc.identifier.emailLai, CL:hrmelcl@hku.hken_HK
dc.identifier.emailWong, BCY:bcywong@hku.hken_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1002/hep.510250144-
dc.identifier.pmid8985298-
dc.identifier.scopuseid_2-s2.0-0031021902en_HK
dc.identifier.hkuros23795en_HK
dc.identifier.hkuros37168-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0031021902&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume25en_HK
dc.identifier.issue1en_HK
dc.identifier.spage241en_HK
dc.identifier.epage244en_HK
dc.identifier.isiWOS:A1997WA90200044-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.scopusauthoridChing, CK=7102130825en_HK
dc.identifier.scopusauthoridTung, AKM=16949551900en_HK
dc.identifier.scopusauthoridLi, E=7201410293en_HK
dc.identifier.scopusauthoridYoung, J=16949957200en_HK
dc.identifier.scopusauthoridHill, A=7403278430en_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK
dc.identifier.scopusauthoridDent, J=7201577625en_HK
dc.identifier.scopusauthoridWu, PC=7403119323en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats